Exhibits receptor serine/threonine kinase binding activity. Involved in several processes, including conditioned place preference; positive regulation of ion transport; and response to alkaloid. Localizes to several cellular components, including integral component of postsynaptic membrane; integral component of synaptic vesicle membrane; and perikaryon. Used to study heroin dependence; myocardial infarction; and withdrawal disorder. Orthologous to human OPRK1 (opioid receptor kappa 1); PARTICIPATES IN nalbuphine pharmacodynamics pathway; INTERACTS WITH (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin; (R)-noradrenaline; (R,R)-tramadol.
Magnesium promotes the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRK1 protein], Manganese promotes the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRK1 protein]
[Tramadol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Tramadol binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Serotonin
[U 69593 binds to and results in increased activity of OPRK1 protein] inhibits the reaction [Cocaine affects the abundance of Dopamine], Cocaine affects the reaction [enadoline binds to OPRK1 protein]
[Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin
Dynorphins binds to and results in increased activity of OPRK1 protein, norbinaltorphimine inhibits the reaction [Dynorphins binds to and results in increased activity of OPRK1 protein]
[Levallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Levorphanol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Serotonin
[Methadone binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Methadone binds to OPRK1 protein] which results in decreased uptake of Serotonin
mitragynine inhibits the reaction [3, 4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer binds to and results in increased activity of OPRK1 protein]
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA
[Tramadol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine, [Tramadol binds to OPRK1 protein] which results in decreased uptake of Serotonin
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA
[U 69593 binds to and results in increased activity of OPRK1 protein] inhibits the reaction [Cocaine affects the abundance of Dopamine], U 69593 binds to and results in increased activity of OPRK1 protein
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPRK1 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPRK1 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
